Ieq Capital LLC Makes New Investment in Illumina, Inc. $ILMN

Ieq Capital LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 267,932 shares of the life sciences company’s stock, valued at approximately $47,111,000. Ieq Capital LLC owned approximately 0.18% of Illumina at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Elyxium Wealth LLC bought a new stake in Illumina in the fourth quarter worth $25,000. TD Waterhouse Canada Inc. bought a new position in Illumina during the fourth quarter valued at $26,000. Laurel Wealth Advisors LLC bought a new position in Illumina during the fourth quarter valued at $26,000. Activest Wealth Management grew its stake in shares of Illumina by 671.9% in the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after buying an additional 215 shares in the last quarter. Finally, Keating Financial Advisory Services Inc. purchased a new position in shares of Illumina in the 2nd quarter worth $32,000. 89.42% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ILMN has been the topic of several recent research reports. JPMorgan Chase & Co. upped their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research report on Wednesday, August 5th. Leerink Partners upped their price objective on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Illumina has a consensus rating of “Hold” and a consensus price target of $188.40.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 457,858 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,095,958 shares of company stock worth $401,720,974 over the last 90 days. Company insiders own 2.90% of the company’s stock.

Illumina Price Performance

Illumina stock opened at $219.40 on Friday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $220.43. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a 50-day moving average price of $188.01 and a 200-day moving average price of $152.44. The firm has a market capitalization of $33.13 billion, a PE ratio of 40.93, a price-to-earnings-growth ratio of 3.00 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the firm posted $1.19 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s latest quarterly results exceeded expectations, with earnings of $1.31 per share versus the $1.23 consensus estimate and revenue of $1.16 billion versus expectations of $1.13 billion. Revenue increased 9.4% year over year, while fiscal 2026 EPS guidance remains $5.30-$5.40. Illumina stock information
• Positive Sentiment: Several institutional investors increased their positions, including Marshall Wace, Cresset Asset Management and Empowered Funds. Hedge funds and other institutions collectively own approximately 89.4% of ILMN shares, indicating strong professional-investor participation.
• Neutral Sentiment: Analyst opinions remain mixed. Zacks Research upgraded the stock to “strong buy,” and Leerink Partners raised its target to $210, while Deutsche Bank downgraded the shares to “hold.” The overall consensus rating is “hold,” with an average target of $188.40—below recent trading levels. Analyst coverage of Illumina
• Negative Sentiment: Director Keith A. Meister sold 679,574 Illumina shares from August 19 through August 21 for approximately $145.6 million. The transactions reduced his ownership by roughly one-third, although he still holds about 1.41 million shares. The size and timing of the sales may raise concerns about insider conviction, even though the filings do not establish the reason for the transactions. SEC insider ownership filing
• Negative Sentiment: SVP Christensen Jakob Wedel also sold 1,033 shares under a pre-arranged Rule 10b5-1 trading plan. The smaller, planned transaction is less concerning than Meister’s sales but adds to the recent pattern of insider selling. Illumina insider trading alert

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.